These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38885537)

  • 1. Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration.
    Ji N; Li H; Zhang Y; Li Y; Wang P; Chen X; Liu YN; Wang JQ; Yang Y; Chen ZS; Li Y; Wang R; Kong D
    Drug Resist Updat; 2024 Sep; 76():101100. PubMed ID: 38885537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
    De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
    Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.
    Cai CY; Zhang W; Wang JQ; Lei ZN; Zhang YK; Wang YJ; Gupta P; Tan CP; Wang B; Chen ZS
    Biochem Pharmacol; 2020 May; 175():113848. PubMed ID: 32044354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.
    Wang J; Yang DH; Yang Y; Wang JQ; Cai CY; Lei ZN; Teng QX; Wu ZX; Zhao L; Chen ZS
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
    Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
    Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
    Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1.
    Wang F; Li D; Zheng Z; Kin Wah To K; Chen Z; Zhong M; Su X; Chen L; Fu L
    J Exp Clin Cancer Res; 2020 Mar; 39(1):50. PubMed ID: 32164732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
    Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
    Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
    Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
    Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
    Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
    Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
    Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.